Portola Pharma (PTLA) Misses Q1 EPS by 9c

Portola Pharma (NASDAQ: PTLA) reported Q1 EPS of ($1.15), $0.09 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $7.91 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c